The study investigates the secondary metabolites produced by Shigella dysenteriae and their antifungal activity, identifying 40 bioactive compounds in its methanolic extract. The research demonstrates that these metabolites, particularly volatile compounds, effectively suppress the growth of Aspergillus flavus, showing a zone of inhibition of 6.00 mm. The findings highlight the potential of Shigella dysenteriae's metabolites for pharmaceutical applications in treating various diseases.